Didanosine Delayed-Release Enteric-Coated Capsules and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration of ritonavir (600 mg every 12 hours) and didanosine (200 mg every 12 hours) has produced a 13% decrease in the area under the plasma concentration-time curve of didanosine. The plasma level of ritonavir was not affected. This interaction is likely to be of minimal clinical significance and dosage adjustments for didanosine are probably not necessary.

Didanosine Delayed-Release Enteric-Coated Capsules

Generic Name: didanosine

Brand name: Videx, Videx EC

Synonyms: Didanosine

What is Didanosine Delayed-Release Enteric-Coated Capsules?

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets

Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir

Brand name: Viekira XR, Viekira Pak

Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets, and Dasabuvir

What is Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets?